Phase II Study to Determine the Efficacy and Safety of PIKA Rabies Vaccine Containing the PIKA Adjuvant With an Accelerated Regimen
Phase of Trial: Phase II
Latest Information Update: 12 Nov 2017
At a glance
- Drugs Rabies vaccine Yisheng Biopharma (Primary) ; Rabies vaccine
- Indications Rabies
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Yisheng Biopharma
- 12 Nov 2017 Primary endpoint (Proportion of subjects with an RVNA titer of 0.5IU/ml at Day 14-non-inferiority) has been met, according to results published in the Vaccine Journal.
- 12 Nov 2017 Results published in the Vaccine Journal.
- 03 Nov 2016 Status changed from recruiting to completed.